心臟衰竭檢測 (POC) 和局部檢測 (LOC) 設備市場：按測試類型、設備類型、技術和最終用戶分類 - 2026-2032 年全球市場預測

預計到 2025 年，心臟衰竭POC 和 LOC 設備的市值將達到 3.0192 億美元，到 2026 年將成長到 3.4806 億美元，到 2032 年將達到 7.4492 億美元，年複合成長率為 13.77%。

主要市場統計數據
基準年 2025	3.0192億美元
預計年份：2026年	3.4806億美元
預測年份 2032	7.4492億美元
複合年成長率 (%)	13.77%

全面概述了現代醫療保健中重新定義心臟衰竭即時診斷和第一線診斷的技術、臨床和營運趨勢。

技術進步、醫療服務模式的轉變以及日益精細的生物學見解的融合，正將即時檢測和線下檢測設備推向心臟衰竭管理的前沿。本執行摘要概述了影響臨床、商業、監管和供應鏈等各領域相關人員的最重要趨勢。它揭示了新興診斷技術、醫療設備外形規格以及支付方的期望如何重塑心臟衰竭的檢測和監測地點、時間和方式，並為製造商、醫療系統和投資者提供了寶貴的見解。

生物標記科學、感測器小型化和分散式醫療保健服務進步的融合如何重塑心臟衰竭患者的診斷和監測。

心臟衰竭的治療正在經歷一場變革，這主要得益於新型生物學檢測、醫療設備小型化以及以早期療育和長期監測為核心的新型治療模式的共同推動。基因組學、蛋白質組學和代謝體學檢測的創新正在拓展臨床醫生可用的生物標記範圍，從而能夠對心臟衰竭症候群進行更詳細的表現型分析，並有助於識別先前因臨床異質性而難以發現的治療靶點。同時，基於生物感測器的系統和平台憑藉其增強的成像能力，使得在傳統醫院環境之外進行連續或近即時的生理評估成為可能。

本研究評估了近期美國關稅趨勢如何影響心臟衰竭診斷和監測設備的供應鏈韌性、供應商選擇和產品設計決策。

美國近期關稅調整和貿易政策轉變對服務於心臟衰竭即時檢測和線下治療市場的製造商和經銷商的供應鏈和商業策略產生了複雜的連鎖反應。關稅導致的零件成本上漲可能會對依賴專用感測器、成像模組和進口檢測試劑的醫療設備製造商造成特別顯著的影響。因此，採購團隊面臨著尋找替代供應商、協商長期供應商協議或加快垂直整合的壓力，以維持利潤率並確保供應的連續性。

基於測試方式、醫療設備外形規格、底層技術以及醫療保健環境的多層次細分，我們獲得了寶貴的見解，從而優先考慮臨床檢驗和商業化的途徑。

基於細分市場的洞察揭示了不同的檢測方法和應用情境如何指導心臟衰竭診斷領域的研究和商業化重點。根據檢測類型，市場被分為三類：基因組檢測、代謝組學和蛋白​​質組學，每類檢測都有獨特的優勢。基因組學方法有助於對遺傳風險和治療反應進行分層；代謝組學能夠捕捉與充血和灌注相關的動態代謝異常；蛋白質體學檢測則能揭示與心肌壓力和重塑相關的蛋白質生物標記。這三種檢測類型協同作用，建構了一個多層次的診斷架構，其中分子特徵與生理監測相輔相成，從而改善診斷和預後預測。

美洲、歐洲、中東和非洲以及亞太地區的採用模式和法規存在區域差異，這影響商業化策略和臨床實施。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的醫療設備部署模式、監管方式和夥伴關係模式有顯著影響。在美洲，醫療保健系統日益重視門診管理和價值驅動方法，從而催生了對快速、可操作的診斷和遠端監測解決方案的需求。在此背景下，能夠與電子健康記錄整合並支援護理協調工作流程的醫療設備和平台，以及已被證實能有效降低再入院率和資源利用率的產品，都具有顯著優勢。

分析現有製造商、診斷創新者和利用科技的新參與企業之間的競爭環境，看他們如何互動、建立夥伴關係，並透過臨床證據和服務模式實現差異化。

心臟衰竭即時檢測和線下診療領域的競爭動態呈現出多元化的態勢，既有成熟的醫療設備製造商，也有專注於診斷技術研發的公司，還有以技術主導、整合硬體、檢測方法和分析能力的新興參與企業。成熟的醫療設備製造商利用其與醫療系統長期建立的合作關係以及龐大的供應鏈規模來分銷診斷設備和整合平台，而小規模的創新企業則專注於小眾生物鑑定、新型生物感測器以及以用戶體驗和連接性為優先的軟體監測解決方案。

為製造商和醫療保健系統領導者提供切實可行的策略行動，以加快部署速度、增強供應韌性，並使證據產生與支付方的優先事項保持一致。

產業領導者應優先採取一系列切實可行的措施，以加速臨床部署並確保商業性韌性。首先，產品開發應與可操作的試驗設計保持一致，這些設計應反映具有臨床意義的終點和真實世界的工作流程，並展示對支付方和醫療服務提供者至關重要的結果。這種做法將減少部署障礙，並加強報銷談判。其次，投資供應鏈多元化和零件標準化，以降低關稅衝擊和地緣政治動盪帶來的風險。關鍵零件的雙重採購以及備選製造地的認證將提高業務永續營運，並實現更可預測的交付計劃。

對研究途徑進行透明的解釋，該方法整合了初步訪談、文獻分析和情境分析，從而得出可操作的見解，而無需依賴數值化的市場預測。

本分析整合了對臨床負責人、醫療設備製造商、供應鏈專家和監管顧問的訪談，並輔以對同行評審文獻和已發布的與心臟衰竭診斷和監測相關的監管指南的系統性回顧。主要定性資訊著重於臨床工作流程、設備易用性、籌資策略和商業化障礙。次要資訊提供了生物感測器技術、檢測性能特徵以及影響貿易和報銷的最新政策趨勢的技術背景。調查方法優先採用三角驗證法，以檢驗來自多個資料來源的新主題，並得出可操作的見解，而非僅僅進行市場預測。

本研究透過創新、臨床檢驗和強力的商業化策略如何結合的綜合考察，旨在將診斷和監測方面的進步與心臟衰竭治療的實際改善聯繫起來。

目前，用於心臟衰竭的即時檢測和線下診療設備呈現出快速的技術創新、不斷演進的診療模式以及對供應鏈和政策趨勢日益敏感的特點。新型分子檢測和基於生物感測器的監測技術正在拓展診斷的可能性，而模組化設備架構和數據驅動型服務則正在重新定義其商業性價值。貿易政策和關稅變化帶來的壓力也凸顯了製定穩健的籌資策略策略和高度靈活的生產策略的必要性，這些策略必須確保臨床品質和監管合規性不受影響。

目錄

第1章：序言

第2章：調查方法

• 調查設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查的前提
• 研究限制

第3章執行摘要

• 首席主管觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 產業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 上市策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會映射
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章心臟衰竭即時檢測 (POC) 和遠端檢測 (LOC) 設備市場：按檢測類型分類

• 基因組檢測
• 代謝體學學檢測
• 蛋白質體學檢測

第9章：心臟衰竭即時檢測（POC​​）和遠端檢測（LOC）設備市場：按設備類型分類

• 診斷設備
  • 心臟生物標記分析儀
  • 心臟影像影像設備
  • 心電圖（ECG）
• 穿戴式裝置
  • 體外去心房顫動
  • 心率監測器

第10章：心臟衰竭即時檢測（POC​​）和遠端檢測（LOC）設備市場：按技術分類

• 基於生物感測器的系統
• 基於成像和電阻的平台
• 免疫檢測
• 基於核酸的平台

第11章：心臟衰竭即時檢測和分級診療設備市場：按最終用戶分類

• 輔助住宅及醫療保健設施
• 居家照護設施
• 醫院和診所
• 檢查室

第12章：心臟衰竭即時檢測和分級診療設備市場：按地區分類

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第13章：心臟衰竭即時檢測（POC​​）和遠端檢測（LOC）設備市場：按組別分類

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第14章：心臟衰竭即時檢測（POC​​）和遠端檢測（LOC）設備市場：按國家/地區分類

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第15章：美國心臟衰竭即時檢測與遠端檢測設備市場

第16章：中國心臟衰竭即時檢測與最後一次治療設備的市場

第17章 競爭格局

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• Abbott Laboratories
• ACON Laboratories Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Boston Scientific Corporation
• Cipla Limited
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Fukuda Denshi Co., Ltd.
• Jant Pharmacal Corporation
• Johari Digital India Limited by Syrma SGS
• Koninklijke Philips NV
• LifeSign LLC
• LifeSync
• Luminex Corporation by DiaSorin SpA
• Mitsubishi Chemical Group Corporation
• Nexus Dx, Inc
• Nihon Kohden Corporation
• Quidel Corporation
• Schiller AG
• Shenzhen EDAN Instrument Co., Ltd.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Siemens Healthineers AG
• Spectral Diagnostics Inc.
• Trinity Biotech PLC

The Heart Failure POC & LOC Devices Market was valued at USD 301.92 million in 2025 and is projected to grow to USD 348.06 million in 2026, with a CAGR of 13.77%, reaching USD 744.92 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 301.92 million
Estimated Year [2026]	USD 348.06 million
Forecast Year [2032]	USD 744.92 million
CAGR (%)	13.77%

An integrated overview of technological, clinical, and operational trends redefining heart failure point-of-care and line-of-care diagnostics in modern healthcare

The convergence of technological advances, shifting care delivery models, and increasingly granular biological insights has placed point-of-care and line-of-care devices at the forefront of heart failure management. This executive summary synthesizes the most consequential developments affecting stakeholders across clinical, commercial, regulatory, and supply chain domains. It articulates how emerging diagnostic modalities, device form factors, and payer expectations are reshaping where, when, and how heart failure is detected and monitored, and it frames implications for manufacturers, health systems, and investors.

Across care settings, clinicians demand faster, more actionable data to support treatment adjustments, triage decisions, and remote monitoring. Concurrently, device makers are moving from single-analyte tests toward multiplexed platforms and integrating biosensor and imaging capabilities into wearable and bench devices. As a result, product development cycles increasingly emphasize interoperability, data security, and user-centered design to meet the needs of both acute care and community-based practitioners. The following sections unpack transformative shifts, tariff-driven supply chain effects, and segmentation- and region-specific insights, concluding with pragmatic recommendations and a transparent description of analytical methods used to derive the findings.

How converging advances in biomarker science, sensor miniaturization, and decentralized care delivery are reshaping diagnostics and monitoring for heart failure patients

Heart failure care is undergoing transformative shifts driven by the interplay of novel biological testing, device miniaturization, and new models of care that prioritize early intervention and longitudinal monitoring. Innovations in genomic, proteomic, and metabolomic testing are expanding the range of biomarkers available to clinicians, enabling more nuanced phenotyping of heart failure syndromes and identifying therapeutic targets previously obscured by clinical heterogeneity. In parallel, biosensor-based systems and imaging-enhanced platforms are permitting continuous or near-real-time physiologic assessment outside traditional hospital settings.

These technological shifts are complemented by evolving clinical pathways that move diagnostic intelligence closer to the patient. Wearable devices and ambulatory diagnostic devices now provide sustained physiologic signals that, when integrated with lab-based assays, create hybrid diagnostic profiles that inform personalized titration of therapies. As interoperability and cloud-native analytics mature, care teams can synthesize longitudinal signals with discrete test results to detect decompensation earlier and reduce avoidable admissions. Regulatory frameworks and reimbursement mechanisms are adapting incrementally, incentivizing outcomes-driven deployments while emphasizing data integrity, clinical validation, and patient safety. Taken together, these developments herald a new era in which diagnostic precision, care decentralization, and digital enablement converge to improve heart failure management.

Assessing how recent United States tariff dynamics are shaping supply chain resilience, sourcing choices, and product design decisions for heart failure diagnostic and monitoring devices

Recent tariff adjustments and trade policy shifts in the United States create complex downstream effects on the supply chains and commercial strategies of manufacturers and distributors serving heart failure point-of-care and line-of-care markets. Tariff-driven increases in component costs can disproportionately affect device makers that rely on specialized sensors, imaging modules, and imported assay reagents. As a result, procurement teams face pressure to seek alternative sourcing, negotiate longer-term supplier agreements, or accelerate vertical integration to preserve margin and ensure continuity of supply.

Beyond direct cost implications, tariffs influence strategic choices such as regional manufacturing footprints, inventory policy, and product design decisions that favor modularity and component standardization. Companies are responding by diversifying suppliers across geographies, qualifying secondary manufacturing sites, and redesigning devices to minimize reliance on tariff-sensitive inputs. For clinical partners and health systems, these changes may alter device availability timelines and necessitate adaptive purchasing strategies that prioritize validated alternatives and accelerate clinical validation of locally sourced technologies. Importantly, regulatory compliance and quality assurance remain non-negotiable during supply chain shifts, and stakeholders must balance speed with rigorous clinical and safety oversight to maintain patient trust and system resilience.

Insights informed by layered segmentation of test modalities, device form factors, enabling technologies, and care settings to prioritize clinical validation and commercialization pathways

Segmentation-driven insight reveals how different modalities and use cases are steering research and commercialization priorities within the heart failure diagnostic landscape. Based on test type, the market is studied across genomic testing, metabolomic testing, and proteomic testing, each offering distinct advantages: genomic approaches help stratify inherited risk and therapy response, metabolomic profiling captures dynamic metabolic derangements linked to congestion and perfusion, and proteomic assays illuminate protein biomarkers that correlate with myocardial stress and remodeling. Together, these test types support a layered diagnostic architecture in which molecular signatures complement physiologic monitoring to refine diagnosis and prognostication.

Based on device type, the market is studied across diagnostic devices and wearable devices. Diagnostic devices are further studied across cardiac biomarker analyzers, cardiac imaging devices, and electrocardiogram (ECG) systems. Cardiac biomarker analyzers enable point-of-care quantification of peptides and enzymes critical for acute assessment, while compact imaging and impedance platforms extend structural and hemodynamic evaluation to non-traditional settings. Electrocardiogram systems remain foundational for rhythm and conduction assessment and are increasingly integrated into multimodal diagnostic suites. Wearable devices are further studied across external defibrillators and heart rate monitors, reflecting a spectrum that ranges from life-saving emergency interventions to continuous physiologic surveillance that supports early intervention.

Based on technology, the market is studied across biosensor-based systems, imaging & impedance-based platforms, immunoassays, and nucleic acid-based platforms. Biosensor-based systems drive continuous, minimally invasive monitoring; imaging and impedance technologies add structural and fluid status context; immunoassays provide rapid protein-based quantification; and nucleic acid platforms facilitate precision-level molecular diagnostics. Based on end user, the market is studied across assisted living healthcare, home care facilities, hospitals & clinics, and laboratory settings, each with unique operational constraints, staffing models, and data integration requirements. When considered together, these segmentation layers reveal where investment and clinical validation should concentrate to create interoperable, clinically actionable diagnostic pathways across care environments.

Regional adoption patterns and regulatory heterogeneity across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence commercialization strategies and clinical deployment

Regional dynamics materially influence device adoption patterns, regulatory approaches, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, health systems increasingly emphasize outpatient management and value-based initiatives that create demand for rapid, actionable diagnostics and remote monitoring solutions. This environment favors devices and platforms that integrate with electronic medical records and support care-coordination workflows, as well as those that demonstrate impact on readmissions and resource utilization.

Across Europe, Middle East & Africa, diverse regulatory landscapes and reimbursement models shape adoption heterogeneously. High-income European markets often prioritize clinical validation and interoperability standards, while resource-constrained settings focus on cost-effectiveness and robustness. As a result, manufacturers must tailor market-entry strategies to local regulatory requirements and demonstrate pragmatic benefits in both tertiary centers and community settings. In the Asia-Pacific region, rapid adoption of digital health, large population cohorts, and growing local manufacturing capacity generate opportunities for scalable deployments of biosensor-enabled wearables and compact diagnostic devices. Strategic partnerships with regional distributors and clinical networks accelerate validation and uptake, while localization efforts in design and service support enhance user adoption. Across all regions, data governance, privacy compliance, and supply chain stability remain critical considerations for successful commercialization.

Analyzing competitive forces where incumbent manufacturers, diagnostics innovators, and tech-enabled entrants converge to form partnerships and differentiate through clinical evidence and service models

Competitive dynamics in the heart failure point-of-care and line-of-care space reflect a mix of established medical device firms, specialized diagnostics developers, and technology-focused entrants that blend hardware, assays, and analytics. Established device manufacturers leverage legacy relationships with health systems and supply chain scale to distribute diagnostic devices and integrated platforms, while smaller innovators focus on niche biologic assays, novel biosensors, and software-enabled monitoring solutions that prioritize user experience and connectivity.

Collaborations between device makers and clinical research networks are increasingly common because co-development helps accelerate real-world validation and payer engagement. Strategic alliances, licensing arrangements, and OEM partnerships enable rapid scaling while preserving clinical credibility. Additionally, the integration of analytics and cloud services creates new value propositions around predictive maintenance, population health management, and remote patient management. As a result, companies that can demonstrate clinical utility, regulatory compliance, and secure data interoperability gain a competitive advantage. Supply chain adaptability, modular product architectures, and the ability to offer bundled hardware-plus-service models further distinguish market leaders from niche players. Ultimately, the competitive landscape rewards organizations that align rigorous clinical evidence generation with nimble commercial execution and robust post-market support.

Practical strategic actions for manufacturers and health system leaders to accelerate adoption, strengthen supply resilience, and align evidence generation with payer priorities

Industry leaders should prioritize a set of actionable measures that accelerate clinical adoption and safeguard commercial resilience. First, align product development with clinically meaningful endpoints and pragmatic trial designs that reflect real-world workflows and demonstrate outcomes that matter to payers and providers. This focus reduces time-to-adoption friction and strengthens reimbursement discussions. Second, invest in supply chain diversification and component standardization to reduce exposure to tariff shocks and geopolitical disruption. Dual-sourcing critical components and qualifying alternate manufacturing sites will enhance continuity and enable more predictable delivery schedules.

Third, design devices and software with interoperability and cybersecurity by default, ensuring seamless integration with electronic health records and remote monitoring platforms while protecting patient data. Fourth, pursue strategic partnerships with care networks and home health providers to validate care models that leverage diagnostic and wearable combinations, enabling smoother commercialization pathways. Fifth, adopt flexible commercial models that combine device sales with subscription-based analytics and service agreements to create recurring revenue and deeper system integration. Finally, maintain an active engagement with regulators and payers to shape pragmatic evidence requirements and to accelerate pathways for reimbursement that reflect real-world value.

Transparent description of the research approach integrating primary interviews, literature synthesis, and scenario analysis to derive actionable insights without relying on numerical market forecasts

This analysis synthesizes primary interviews with clinical leaders, device manufacturers, supply chain experts, and regulatory advisors, complemented by a systematic review of peer-reviewed literature and public regulatory guidance relevant to heart failure diagnostics and monitoring. Primary qualitative input focused on clinical workflows, device usability, sourcing strategies, and commercialization hurdles. Secondary sources provided technical context on biosensor technologies, assay performance characteristics, and recent policy shifts influencing trade and reimbursement. The methodology prioritized triangulation to validate emergent themes across multiple data sources and to surface actionable insights rather than raw market estimates.

Analytical steps included mapping the diagnostic and device ecosystem by test type, device form factor, enabling technology, and end-user environment to reveal where clinical need and technical feasibility align. Scenario analysis explored supply chain responses to tariff and trade policy changes, emphasizing operational strategies that preserve quality and continuity. Evidence synthesis highlighted recurring barriers to adoption-such as integration burden, clinical validation gaps, and reimbursement uncertainty-and identified levers for acceleration including strategic partnerships, localized manufacturing, and flexible commercial models. Wherever applicable, findings were cross-validated with domain experts to ensure relevance and practical applicability for decision-makers.

Synthesis of how innovation, clinical validation, and resilient commercialization strategies must converge to turn diagnostic and monitoring advances into tangible improvements in heart failure care

The landscape of heart failure point-of-care and line-of-care devices is marked by rapid technical innovation, evolving care models, and heightened sensitivity to supply chain and policy dynamics. New molecular tests and biosensor-enabled monitoring are expanding diagnostic possibilities, while modular device architectures and data-driven services are redefining commercial value. Concurrent pressures from trade policy and tariff changes underscore the need for resilient sourcing and adaptive manufacturing strategies that do not compromise clinical quality or regulatory compliance.

Looking ahead, stakeholders who integrate rigorous clinical validation with pragmatic commercialization approaches and robust supply chain planning will be best positioned to capture clinical trust and operational scale. Cross-sector collaboration among manufacturers, care providers, payers, and regulators remains essential to translate technological promise into sustained improvements in patient outcomes. By focusing on interoperability, evidence generation tied to meaningful clinical endpoints, and flexible deployment models suited to regional contexts, organizations can accelerate the adoption of diagnostic and wearable solutions that meaningfully improve heart failure management across care settings.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Heart Failure POC & LOC Devices Market, by Test Type

• 8.1. Genomic Testing
• 8.2. Metabolomic Testing
• 8.3. Proteomic Testing

9. Heart Failure POC & LOC Devices Market, by Device Type

• 9.1. Diagnostic Devices
  • 9.1.1. Cardiac Biomarker Analyzers
  • 9.1.2. Cardiac Imaging Devices
  • 9.1.3. Electrocardiogram (ECG)
• 9.2. Wearable Devices
  • 9.2.1. External Defibrillator
  • 9.2.2. Heart Rate Monitors

10. Heart Failure POC & LOC Devices Market, by Technology

• 10.1. Biosensor-based systems
• 10.2. Imaging & impedance-based platforms
• 10.3. Immunoassays
• 10.4. Nucleic acid-based platforms

11. Heart Failure POC & LOC Devices Market, by End User

• 11.1. Assisted Living Healthcare
• 11.2. Home Care Facilities
• 11.3. Hospitals & Clinics
• 11.4. Laboratory

12. Heart Failure POC & LOC Devices Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Heart Failure POC & LOC Devices Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Heart Failure POC & LOC Devices Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Heart Failure POC & LOC Devices Market

16. China Heart Failure POC & LOC Devices Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Abbott Laboratories
• 17.6. ACON Laboratories Inc.
• 17.7. Becton, Dickinson and Company
• 17.8. Bio-Rad Laboratories, Inc.
• 17.9. bioMerieux S.A.
• 17.10. Boston Scientific Corporation
• 17.11. Cipla Limited
• 17.12. Danaher Corporation
• 17.13. F. Hoffmann-La Roche Ltd.
• 17.14. Fukuda Denshi Co., Ltd.
• 17.15. Jant Pharmacal Corporation
• 17.16. Johari Digital India Limited by Syrma SGS
• 17.17. Koninklijke Philips N.V.
• 17.18. LifeSign LLC
• 17.19. LifeSync
• 17.20. Luminex Corporation by DiaSorin S.p.A.
• 17.21. Mitsubishi Chemical Group Corporation
• 17.22. Nexus Dx, Inc
• 17.23. Nihon Kohden Corporation
• 17.24. Quidel Corporation
• 17.25. Schiller AG
• 17.26. Shenzhen EDAN Instrument Co., Ltd.
• 17.27. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 17.28. Siemens Healthineers AG
• 17.29. Spectral Diagnostics Inc.
• 17.30. Trinity Biotech PLC

LIST OF FIGURES

• FIGURE 1. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 12. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 63. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 64. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 65. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 66. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 67. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 68. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 69. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 70. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 71. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 72. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 73. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 74. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 75. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 76. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 77. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 78. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 79. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 80. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 81. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 82. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 83. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 90. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 91. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 92. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 93. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 94. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 95. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 96. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 97. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 98. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 99. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 100. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 101. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 102. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 103. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 104. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 105. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 107. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 108. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 109. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 110. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 111. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 112. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 113. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 114. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 115. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 116. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 117. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 118. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 119. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 120. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 121. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 122. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 123. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 124. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 125. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 126. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 127. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 128. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 129. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 130. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 131. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 132. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 133. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 134. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 135. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 136. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 137. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 138. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 139. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 140. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 141. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 142. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 143. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 144. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 145. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 146. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 147. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 148. G7 HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 149. G7 HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 150. G7 HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 151. G7 HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 152. G7 HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 153. G7 HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 154. G7 HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 155. NATO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 156. NATO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 157. NATO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 158. NATO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 159. NATO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 160. NATO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 161. NATO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 162. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 163. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 164. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 165. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 166. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 167. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 168. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 169. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 170. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 171. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
• TABLE 172. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 173. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
• TABLE 174. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2032 (USD MILLION)
• TABLE 175. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 176. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)